公开(公告)号：US20190169185A1

公开(公告)日：2019-06-06

申请号：US16204584

申请日：2018-11-29

Applicant: ARBUTUS BIOPHARMA, INC.

Inventor： RAMESH D. KAKARLA ,  BRUCE D. DORSEY

IPC: C07D471/04 ,  A61K31/4375 ,  A61K45/06 ,  A61P31/20

CPC classification number: C07D471/04 ,  A61K31/4375 ,  A61K45/06 ,  A61P31/20

Abstract: The present invention includes novel substituted 2-N-hydroxy-1,3-dioxo-1,2,3,4-tetrahydronaphthyridines, which can be used to treat or prevent hepatitis B virus (HBV) infections in a patient. In certain embodiments, the compounds and compositions of the invention inhibit HBV RNAse H activity.

公开(公告)号：US20190142827A1

公开(公告)日：2019-05-16

申请号：US16261353

申请日：2019-01-29

Applicant: Curegenix, Inc.

Inventor： Songzhu An

IPC: A61K31/4985 ,  A61K31/497 ,  A61K31/541 ,  A61K31/5377 ,  A61K31/506 ,  A61K31/501 ,  A61K31/496 ,  A61K31/4375 ,  A61K31/4725 ,  A61K31/472 ,  A61K31/444

CPC classification number: A61K31/4985 ,  A61K31/4375 ,  A61K31/444 ,  A61K31/472 ,  A61K31/4725 ,  A61K31/496 ,  A61K31/497 ,  A61K31/501 ,  A61K31/5025 ,  A61K31/506 ,  A61K31/519 ,  A61K31/5377 ,  A61K31/541

Abstract: The present invention relates to compounds as inhibitor of WNT signal transduction pathway, as well as a composition comprising the same. Further, the present invention relates to the use of the compounds in the treatment of cancer.

公开(公告)号：US20190010461A1

公开(公告)日：2019-01-10

申请号：US16029068

申请日：2018-07-06

Applicant: Wisconsin Alumni Research Foundation

Inventor： James A. Thomson ,  Jue Zhang

IPC: C12N5/077 ,  A61K31/4375

CPC classification number: C12N5/0661 ,  A61K31/4375 ,  C12N5/0606 ,  C12N2501/115 ,  C12N2501/135 ,  C12N2501/15 ,  C12N2501/155 ,  C12N2501/16 ,  C12N2501/165 ,  C12N2501/42 ,  C12N2501/999 ,  C12N2506/02 ,  C12N2506/03 ,  C12N2506/04 ,  C12N2510/00 ,  C12N2533/90

Abstract: Methods of using a small molecule MYH11 agonist to inhibit intimal hyperplasia and to maintain a contractile phenotype in vitro and in vivo are described. Also described herein are methods for generating human contractile smooth muscle cells from human pluripotent stem cells under defined conditions in the presence of the small molecule MYH11 agonist.

公开(公告)号：US20180333406A1

公开(公告)日：2018-11-22

申请号：US15429087

申请日：2017-02-09

Applicant: GlaxoSmithKline Biologicals SA ,  U.S. Army Medical Research and Materiel Command

Inventor： Gillis OTTEN ,  Tom Yao-Hsiang WU ,  Travis K. WARREN ,  Sina BAVARI

IPC: A61K31/4745 ,  A61K31/4375 ,  A61K33/06 ,  A61K38/16

CPC classification number: A61K31/4745 ,  A61K31/4375 ,  A61K33/06 ,  A61K38/162 ,  A61K2300/00

Abstract: The present invention generally relates to compositions comprising benzonapthyridine small molecule immune potentiators (SMIPs) that are capable of stimulating or modulating an immune response in a subject that has had pre- or post-exposure to a pathogen such as hemorrhagic fever virus. Also provided are methods of preparing and using the SMIP compositions of the invention.

公开(公告)号：US20180327495A1

公开(公告)日：2018-11-15

申请号：US16041399

申请日：2018-07-20

Applicant: Immunomedics, Inc.

Inventor： David M. Goldenberg ,  Thomas M. Cardillo

IPC: C07K16/28 ,  A61K31/337 ,  A61K39/395 ,  A61K31/502 ,  A61K31/519 ,  A61K31/4745 ,  A61K31/52 ,  A61P35/00 ,  A61K31/357 ,  A61K45/06 ,  A61K31/4184 ,  A61K31/4375 ,  A61K31/454 ,  A61K31/513 ,  A61K31/675 ,  A61K31/7088 ,  A61K31/713 ,  A61K33/24 ,  C07K16/30 ,  A61K47/68

CPC classification number: A61K47/6853 ,  A61K31/337 ,  A61K31/357 ,  A61K31/4184 ,  A61K31/4375 ,  A61K31/454 ,  A61K31/4745 ,  A61K31/502 ,  A61K31/513 ,  A61K31/519 ,  A61K31/52 ,  A61K31/675 ,  A61K31/7088 ,  A61K31/713 ,  A61K33/24 ,  A61K39/3955 ,  A61K39/39558 ,  A61K45/06 ,  A61K47/6803 ,  A61K47/6809 ,  A61K47/6849 ,  A61K47/6851 ,  A61K2039/505 ,  A61P35/00 ,  C07K16/2803 ,  C07K16/2833 ,  C07K16/2887 ,  C07K16/30 ,  C07K16/3007 ,  C07K2317/24 ,  C07K2317/92 ,  C07K2317/94 ,  A61K2300/00

Abstract: The present invention relates to combination therapy with drugs, such as Bruton's tyrosine kinase inhibitors or PI3K inhibitors, with antibodies or ADCs against HLA-DR. Where ADCs are used, they preferably incorporate SN-38 or pro-2PDOX. The ADC may be administered at a dosage of between 1 mg/kg and 18 mg/kg, preferably 4, 6, 8, 9, 10, 12, 16 or 18 mg/kg. The combination therapy can reduce solid tumors in size, reduce or eliminate metastases and is effective to treat cancers resistant to standard therapies, such as radiation therapy, chemotherapy or immunotherapy. Preferably, the combination therapy has an additive effect on inhibiting tumor growth. Most preferably, the combination therapy has a synergistic effect on inhibiting tumor growth.

公开(公告)号：US20180311298A1

公开(公告)日：2018-11-01

申请号：US16028812

申请日：2018-07-06

Applicant: GDB Patent Holdings, LLC

Inventor： Gregory Blackman

IPC: A61K36/752 ,  A61K45/06 ,  A23L33/175 ,  A61K36/28 ,  A61K31/732 ,  A61K31/714 ,  A61K31/525 ,  A61K31/519 ,  A61K31/51 ,  A61K31/455 ,  A61K31/4415 ,  A61K31/4375 ,  A61K31/4015 ,  A61K31/352 ,  A61K31/198 ,  A61K31/197 ,  A61K31/137 ,  A61K31/133 ,  A61K9/08 ,  A61K9/00 ,  A61K36/73 ,  A23L33/16 ,  A23L33/15 ,  A23L33/21 ,  A61K8/31 ,  A61K8/19 ,  A61K8/67

CPC classification number: A61K36/752 ,  A23L33/15 ,  A23L33/16 ,  A23L33/175 ,  A23L33/21 ,  A23V2002/00 ,  A61K8/19 ,  A61K8/31 ,  A61K8/67 ,  A61K8/673 ,  A61K9/0095 ,  A61K9/08 ,  A61K31/133 ,  A61K31/137 ,  A61K31/197 ,  A61K31/198 ,  A61K31/352 ,  A61K31/4015 ,  A61K31/4375 ,  A61K31/4415 ,  A61K31/455 ,  A61K31/51 ,  A61K31/519 ,  A61K31/525 ,  A61K31/714 ,  A61K31/732 ,  A61K36/28 ,  A61K36/73 ,  A61K45/06 ,  A61K2300/00 ,  A23V2200/334 ,  A23V2250/0616 ,  A23V2250/0634 ,  A23V2250/16 ,  A23V2250/161 ,  A23V2250/1614 ,  A23V2250/21168 ,  A23V2250/5072 ,  A23V2250/7042 ,  A23V2250/7044 ,  A23V2250/7046 ,  A23V2250/705 ,  A23V2250/7052 ,  A23V2250/706 ,  A23V2250/0652 ,  A23V2250/7054 ,  A23V2250/7058

Abstract: The present invention relates to a composition, and methods of using the composition, for minimizing the harmful effects associated with alcohol consumption. The composition includes a plurality of ingredients, which when combined, have the unexpected effect of increasing one or more metabolic pathways in the individual. As the metabolic rate is increased, alcohol is burned off, or utilized as energy source, and occurs at a considerably much faster rate than under normal physiological means. It is believed that the composition may have an effect on the brain causing it to increase metabolic rates. By administering the composition to an inebriated individual, the rate at which a person sobers up, occurs at a faster rate than would occur under normal physiological time frames.

公开(公告)号：US20180305312A1

公开(公告)日：2018-10-25

申请号：US15571223

申请日：2016-05-14

Applicant: THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY

Inventor： Troy E. Messick ,  Garry R. Smith ,  Allen B. Reitz ,  Paul M. Lieberman ,  Mark E. McDonnell ,  Yan Zhang ,  Marianne Carlsen ,  Shuai Chen

IPC: C07D209/08 ,  A61K31/5377 ,  C07D405/12 ,  A61K31/404 ,  C07D471/04 ,  A61K31/437 ,  A61K31/541 ,  A61K31/4375 ,  C07D405/14 ,  A61K31/454 ,  C07D401/14 ,  C07D409/12 ,  A61K31/496 ,  C07D403/10 ,  A61K31/41 ,  C07D413/10 ,  A61K31/422 ,  A61K31/501 ,  C07D401/10 ,  A61K31/4725 ,  C07D403/14 ,  C07D401/12 ,  A61K31/4439 ,  C07D403/12 ,  A61K31/506 ,  A61K31/4155 ,  C07D277/62 ,  A61K31/426 ,  C07D491/107 ,  A61K31/435 ,  C07D417/10 ,  A61K31/427 ,  A61K31/433 ,  A61K31/517 ,  A61K31/519 ,  A61K31/551 ,  C07D487/04 ,  C07D471/10 ,  A61K45/06 ,  A61P31/20

CPC classification number: C07D209/08 ,  A61K31/404 ,  A61K31/41 ,  A61K31/4155 ,  A61K31/422 ,  A61K31/426 ,  A61K31/427 ,  A61K31/433 ,  A61K31/435 ,  A61K31/437 ,  A61K31/4375 ,  A61K31/4439 ,  A61K31/454 ,  A61K31/4725 ,  A61K31/496 ,  A61K31/501 ,  A61K31/506 ,  A61K31/517 ,  A61K31/519 ,  A61K31/5377 ,  A61K31/541 ,  A61K31/551 ,  A61K45/06 ,  A61P31/20 ,  A61P35/00 ,  C07D277/62 ,  C07D401/10 ,  C07D401/12 ,  C07D401/14 ,  C07D403/10 ,  C07D403/12 ,  C07D403/14 ,  C07D405/12 ,  C07D405/14 ,  C07D409/12 ,  C07D413/10 ,  C07D417/10 ,  C07D417/12 ,  C07D471/04 ,  C07D471/08 ,  C07D471/10 ,  C07D487/04 ,  C07D487/08 ,  C07D491/107

Abstract: The present invention provides EBNA1 inhibitors, and/or pharmaceutical compositions comprising the same, that are useful for the treatment of diseases caused by EBNA1 activity, such as, but not limited to, cancer, infectious mononucleosis, chronic fatigue syndrome, multiple sclerosis, systemic lupus erythematosus and/or rheumatoid arthritis. The present invention further provides EBNA1 inhibitors, and/or pharmaceutical compositions comprising the same, that are useful for the treatment of diseases caused by latent Epstein-Barr Virus (EBV) infection and/or lytic EBV infection.

公开(公告)号：US20180303807A1

公开(公告)日：2018-10-25

申请号：US15765140

申请日：2016-10-01

Applicant: John KATZENELLENBOGEN ,  Jatinder JOSAN ,  DUKE UNIVERSITY ,  BOARD OF TRUSTEES OF SOUTHERN ILLINOIS UNIVERSITY ,  VIRGINIA POLYTECHNIC INSTITUTE AND STATE UNIVERSITY

Inventor： John A. Katzenellenbogen ,  Jatinder Josan ,  John Norris ,  Donald P. McDonnell

IPC: A61K31/4375 ,  A61P35/00 ,  A61K31/4365

CPC classification number: A61K31/4375 ,  A61K31/4365 ,  A61P35/00 ,  C07D219/08 ,  C07D221/02 ,  C07D311/78 ,  C07D401/04 ,  C07D405/04 ,  C07D409/04 ,  C07D417/10 ,  C07D471/04 ,  C07D471/14 ,  C07D495/14

Abstract: Described are compounds that inhibit androgen receptor action, pharmaceutical compositions including the compounds, and methods of using the compounds and compositions for treating disorders and conditions in a subject.

公开(公告)号：US20180303802A1

公开(公告)日：2018-10-25

申请号：US15766192

申请日：2016-10-05

Applicant: THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY

Inventor： Cigall KADOCH ,  Gerald R. CRABTREE

IPC: A61K31/427 ,  A61P35/00 ,  A61K31/395 ,  A61K31/437

CPC classification number: A61K31/427 ,  A61K31/395 ,  A61K31/437 ,  A61K31/4375 ,  A61P35/00

Abstract: Methods useful in the treatment of synovial sarcoma are provided. The methods comprise administering to a subject suffering from synovial sarcoma a compound as disclosed herein. Also provided are novel compounds having therapeutic effects on subjects suffering from synovial sarcoma and pharmaceutical compositions comprising the compounds. The compounds were identified by screening for agents that promote the assembly of wild-type BAF (also called mSWI/SNF) complexes in modified SS cells.

公开(公告)号：US20180282328A1

公开(公告)日：2018-10-04

申请号：US15942321

申请日：2018-03-30

Applicant: Genentech, Inc.

Inventor： Bryan Chan ,  Blake Daniels ,  Joy Drobnick ,  Lewis Gazzard ,  Timothy Heffron ,  Malcolm Huestis ,  Jun Liang ,  Sushant Malhotra ,  Rohan Mendonca ,  Naomi Rajapaksa ,  Michael Siu ,  Craig Stivala ,  John Tellis ,  Weiru Wang ,  BinQing Wei ,  Aihe Zhou ,  Matthew W. Cartwright ,  Emanuela Gancia ,  Graham Jones ,  Michael Lainchbury ,  Andrew Madin ,  Eileen Seward ,  David Favor ,  Kin Chiu Fong ,  Andrew Good ,  Yonghan Hu ,  Baihua Hu ,  Aijun Lu

IPC: C07D471/04 ,  A61K45/06 ,  A61P35/00 ,  A61K31/444 ,  A61K31/4375 ,  A61K31/506 ,  C07D519/00 ,  A61K31/4545 ,  A61K31/4725 ,  A61K31/5383 ,  A61K31/496 ,  A61K31/5377 ,  A61K31/5025 ,  A61K31/551 ,  A61K31/55

CPC classification number: C07D471/04 ,  A61K31/4375 ,  A61K31/444 ,  A61K31/4545 ,  A61K31/4725 ,  A61K31/496 ,  A61K31/5025 ,  A61K31/506 ,  A61K31/5377 ,  A61K31/5383 ,  A61K31/55 ,  A61K31/551 ,  A61K45/06 ,  A61P35/00 ,  C07D519/00

Abstract: Naphthyridine compounds and their use as inhibitors of HPK1 are described. The compounds are useful in treating HPK1-dependent disorders and enhancing an immune response. Also described are methods of inhibiting HPK1, methods of treating HPK1-dependent disorders, methods for enhancing an immune response, and methods for preparing the naphthyridine compounds.